ArticleThe American journal of case reports2026
Prolonged Tardive Dyskinesia Induced by Long-Acting Paliperidone Palmitate in Schizophrenia: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Tardive dyskinesia is an iatrogenic syndrome that can include dystonia, akathisia, facial tics, chorea, and other abnormal involuntary movements. Tardive dyskinesia follows antipsychotic medication and results from the antagonism of dopamine receptors. This report describes a 40-year-old woman with schizophrenia treated with the long-acting antipsychotic paliperidone palmitate, with persistent tardive dyskinesia, requiring long-term management. CASE REPORT A 40-year-old woman with schizophrenia was administered long-acting paliperidone palmitate for 1 month in April 2017 and then switched to long-acting paliperidone palmitate for 3 months starting in October 2017. After 3 months of long-acting injection exposure (April 2018), she developed sustained cervical posturing and mask-like facies. Dose reduction to 350 mg was ineffective; the long-acting injection was stopped in June 2019, and aripiprazole 10 mg/day was started. Adjuncts (trihexyphenidyl, amantadine, and intermittent benzodiazepines) provided only limited benefit. Clozapine was started in December 2019 and titrated, with gradual, incomplete improvement. On readmission in May 2024, Neurology diagnosed tardive dyskinesia, particularly tardive dystonia. Over 6 years without vesicular monoamine transporter 2 (VMAT-2) inhibitors, her dystonia lessened but persisted, and she was discharged on clozapine and fluvoxamine. CONCLUSIONS Tardive dystonia can follow exposure to long-acting injectable paliperidone and may be prolonged yet partly reversible despite discontinuation. Given therapeutic limits, variable prognosis, and the 3-month formulation's extended pharmacokinetics, clinicians should maintain high suspicion, minimize dopamine-receptor-blocking exposure, and individualize care, considering timely VMAT-2 inhibitors or clozapine, plus structured long-term motor monitoring and shared decision-making. This report highlights the presentation of tardive dyskinesia as a complication of antipsychotic medication and the approach to management of this iatrogenic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.